Indications and usage:
Diseases and conditions requiring high protein production to improve
general condition of the patient.
Recovery period.
Postoperative treatment.
Cachexia.
Radiotheraoy and cytostatic therapy.
Advanced breast cancer and genital cancers in women.
Hematopoiesis disorders,
Long term corticoid treatment.
Osteoporosis.
Protein deficiency in old age and chronic liver diseases to support the recovery process and prevent damage from catabolic processes.
Contraindications:
Previous or present liver lumours, hyper sensitivity to active substance or its components.
Females:
Pregnancy.
Males:
Prostrate or breast carcinoma.
Other hormone-dependant carcinoma.
Drug interactions:
Primobolan may enhance effects of anitidiabetics,cyclosporin, levothyroxine, warfarin Resistance to the effects of neuromuscular blockers may occur.
Overdosage:
There have been no reports of acute overdosage.
Side Effects / Adverse reactions:
Fluid and electrolyte retention;
Psychiatric effects,
Hypercalceamia.
Impaired glucose tolerance,
Increased bone growth and skeletal weight.
Men:
Impotence, priapism, azoospermia, prostatic hypertrophy;
gynaecomastia, hirsutism, male pattern baldness, acne, seborrhoea,oedema, cholestatic jaundice.
Women:
Virilisation, amenorrhoea, menstrual irregularities, suppressed lactation,increased libido.
Children:
Premature closure of epiphyses, stops linear growth, virilisation symptoms.
Precautions/Warnings:
Incase Primobolan is applied during the first days of cycle, menstruation date may delay in women having irregular cycle.
Treatment should be ceased in case of hypercalcemia during hormone administration in women with progressive breast and gental carcinomas.
Administration of Primobolan during pregnancy is contraindicated.
Transition of methenolone and its metabolites to breast milk is not researched Liver function tests should be clinically monitored regularly. Clinically significant increase in liver function parameters or cholestatic requires Primobolan usage to be ceased.
Regular prostate controls are recommended as a precaution.
Treatment should be applied by intervals having reasonable gaps between in order to avoid virilisation symptoms and early development of bones in patients who have not completed growth yet.
Dosage and administration:
Primobolan is administered by intramuscular injection. It must not be
given intravenously. Intramuscular injections should be given deep into
the gluteal muscle.
Postmenopausal Osteoporosis Adult:
Intramuscular- 100mg every 2 weeks, then reduce to once every 3- 4 weeks after the initial response.
Progressive breast cancer Adult:
Intramuscular- 100mg every 1-2 weeks or 200mg every 2-3 weeks
Supplied / Storage:
Primobolan is supplied in 10 x1ml ampules. Ampules should be stored at controlled room temperatures below 30 C and protected from light.
Parenteral drug products should be inspected visually for particulate matter and discolouration prior to administration, whenever solution and container permit. Warming and shaking the ampules should redisolve any crystals that may have formed during storage al temperature lower than recommended. If it has expired or is damaged, retum to your pharmacist.
Keep out of the reach and sight of children.